International collaboration on bird flu vaccine
BioDiem, Nobilon and the US Centres for Disease Control and
Prevention (CDC) have signed a cooperative research and development agreement to
develop a cell culture candidate vaccine against avian influenza
Australia-based pharmaceutical company BioDiem's cooperation with Dutch company Akzo Nobel's Nobilon and the CDC means that BioDiem's live
attenuated intranasal flu vaccine will be advanced through pre-clinical
development at the CDC's high-security laboratories.
According to experts at the World Health Organisation, a live vaccine may offer better and
broader protection in the event of a pandemic outbreak of avian
The co-operative research will generate, characterise and evaluate, in
pre-clinical models, live attenuated cold-adapted influenza vaccine (LAIV)
candidates against influenza A H5N1 viruses.
BioDiem CEO Tom Williams said: "It's a reflection of the potential of this
live attenuated influenza technology that the CDC is contributing its resources
to this program of work on BioDiem's flu vaccine. "
"This is an extremely important collaborative agreement which could prove
crucial in our efforts to develop a vaccine for one of the world's leading
health risks," said Toon Wilderbeek, Akzo Nobel's Board member, responsible for Pharma.
BioDiem has licensed the majority of the LAIV rights to Nobilon, which has
recently received European GMP registration for its new facility in the
Netherlands to begin manufacturing influenza vaccines in cell culture for
clinical trials. BioDiem retains the right to license out the sales and
marketing rights to the world's largest market, North America. Japanese rights
are to be shared with Nobilon.
To comment, login here
Or register to be able to comment.